Display options
Cite
Hawasli AH, Rubin JB, Tran DD, et al. Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base. 2013;74(3):136-41doi: 10.1055/s-0033-1338262.
Hawasli, A. H., Rubin, J. B., Tran, D. D., Adkins, D. R., Waheed, S., Hullar, T. E., Gutmann, D. H., Evans, J., Leonard, J. R., Zipfel, G. J., & Chicoine, M. R. (2013). Antiangiogenic agents for nonmalignant brain tumors. Journal of neurological surgery. Part B, Skull base, 74(3), 136-41. https://doi.org/10.1055/s-0033-1338262
Hawasli, Ammar H, et al. "Antiangiogenic agents for nonmalignant brain tumors." Journal of neurological surgery. Part B, Skull base vol. 74,3 (2013): 136-41. doi: https://doi.org/10.1055/s-0033-1338262
Hawasli AH, Rubin JB, Tran DD, Adkins DR, Waheed S, Hullar TE, Gutmann DH, Evans J, Leonard JR, Zipfel GJ, Chicoine MR. Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base. 2013 Jun;74(3):136-41. doi: 10.1055/s-0033-1338262. Epub 2013 Mar 13. PMID: 24436903; PMCID: PMC3709924.
Copy Download .nbib Format: NLM
Share it on

J Neurol Surg B Skull Base. 2013 Jun;74(3):136-41. doi: 10.1055/s-0033-1338262. Epub 2013 Mar 13.

Antiangiogenic agents for nonmalignant brain tumors.

Journal of neurological surgery. Part B, Skull base

Ammar H Hawasli, Joshua B Rubin, David D Tran, Douglas R Adkins, Shahid Waheed, Timothy E Hullar, David H Gutmann, John Evans, Jeffrey R Leonard, Gregory J Zipfel, Michael R Chicoine

Affiliations

  1. Department of Neurosurgery, Washington University School of Medicine, Saint Louis, Missouri, USA.
  2. Department of Pediatrics, Washington University School of Medicine, Saint Louis, Missouri, USA ; Department of Anatomy and Neurobiology, Washington University School of Medicine, Saint Louis, Missouri, USA.
  3. Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.
  4. J. B. & Greeta B. Arthur Cancer Center, Mexico, Missouri, USA.
  5. Department of Otolaryngology, Washington University School of Medicine, Saint Louis, Missouri, USA ; Department of Anatomy and Neurobiology, Washington University School of Medicine, Saint Louis, Missouri, USA.
  6. Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA.

PMID: 24436903 PMCID: PMC3709924 DOI: 10.1055/s-0033-1338262

Abstract

Objective To assess the treatment response and side effects for the use of antiangiogenic agents such as vascular endothelial growth factor (VEGF) inhibitors for patients with vestibular schwannomas and meningiomas. Design and Methods Retrospective review of eight male and two female patients (ages 14 to 70, mean 36 years), treated with bevacizumab (9) or pazopanib (1). Six patients had neurofibromatosis type 2 (NF2) with bilateral vestibular schwannomas and meningiomas, and the four others had aggressive recurrent meningiomas. Results During treatment (range 4 to 21 months, mean 9.1) with antiangiogenic agents, two patients with an atypical meningioma and radiation necrosis had dramatic partial response, the six NF2 patients had stable or slightly improved disease, and two meningioma patients had disease progression. Hearing was stable in three of the NF2 patients and was improved in three NF2 patients (one of whom received a cochlear implant). Minor toxicities included epistaxis, nausea, diarrhea, weight loss, and abdominal pain. No grade 3 or 4 toxicities were observed. Conclusion Antiangiogenic agents appear to be safe for the treatment of patients with nonmalignant brain tumors, and in select cases may be efficacious.

Keywords: bevacizumab; brain tumor; meningioma; neurofibromatosis; pazopanib; vascular endothelial growth factor; vestibular schwannoma

References

  1. Clin Neuropathol. 2012 Sep-Oct;31(5):352-60 - PubMed
  2. Otol Neurotol. 2005 Jan;26(1):98-101 - PubMed
  3. Neuro Oncol. 2010 Jan;12(1):14-8 - PubMed
  4. Laryngoscope. 2003 Dec;113(12):2129-34 - PubMed
  5. Strahlenther Onkol. 2011 Feb;187(2):135-9 - PubMed
  6. J Neurooncol. 2012 Aug;109(1):187-93 - PubMed
  7. J Neurosurg Sci. 2011 Dec;55(4):319-28 - PubMed
  8. J Neurooncol. 2012 Aug;109(1):63-70 - PubMed
  9. Pediatr Blood Cancer. 2013 May;60(5):776-82 - PubMed
  10. N Engl J Med. 2009 Jul 23;361(4):358-67 - PubMed
  11. Brain Pathol. 1995 Apr;5(2):163-72 - PubMed
  12. J Laryngol Otol. 2004 Aug;118(8):622-7 - PubMed
  13. Cancer. 2012 Oct 15;118(20):5038-49 - PubMed
  14. Genet Mol Res. 2011 Sep 23;10(3):2165-71 - PubMed
  15. Pediatr Blood Cancer. 2009 Jul;52(7):791-5 - PubMed
  16. Ann Oncol. 2010 Nov;21(11):2294-2295 - PubMed
  17. Neurosurgery. 2010 Nov;67(5):1335-40; discussion 1340 - PubMed

Publication Types

Grant support